Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。